[{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/","commit":"f7782c9f5f","date":"2026-09-10","author":"Jude Gomila","message":"Sources: official-website links on a further thirty companies","file":"src/data/spikes/pancreatic.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"Official website\", url: \"https://www.ipsen.com\" }]"}]},{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/","commit":"01c3b96cd7","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch D: Builders and investors","file":"src/data/sponsor-aliases.ts","type":"added","fields":[{"field":"id"},{"field":"label"},{"field":"kind"}]},{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/pancreatic.ts","type":"changed","fields":[{"field":"tldr","before":"\"French pharma behind Onivyde (liposomal irinotecan) and the NALIRIFOX regimen, and marketer of tovorafenib in Europe.\"","after":"\"Ipsen is the French pharma behind Onivyde (liposomal irinotecan) and the NALIRIFOX regimen, and marketer of tovorafenib in Europe.\""}]}]